Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Welcome, that vk2809 data is fairly new. Its the vk5211 P2 results that are due at anytime we are waiting for.
VK5211 for Hip Fracture http://www.vikingtherapeutics.com/pipeline/vk5211/
Nice to see steady growth with both Nevada sales witha 24 % jump and TRTC expansion/growth in Revenue in Q2 and Q3...each Q will be getting better and better as we move forward. In 2018 TRTC stock will be a big winner.
Nevada marijuana sales eclipse $33 million for August 2017
The August totals for Nevada marijuana shops represent a nearly 24 percent jump from the $27.1 million in sales logged in July
http://www.thecannabist.co/2017/10/23/nevada-marijuana-sales-august-2017/90687/
Good info Titan V, thanks for posting that. VKTX , GTXI and MRK are still developing SARM drugs.
where has LGND fail to move a SARM forward ? did LGND ever run a FDA trial with their SARM ? I believe the answer is No.
Are you here to spread misinformation because you shorted VKTX at 2.00 and are desperate to cover ?...i would cover your shorts now ...before it goes much higher on the news.
SAN DIEGO, Oct. 23, 2017 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced positive results from a 25-week proof-of-concept study of VK0214 in an in vivo model of X-linked adrenoleukodystrophy (X-ALD). The final study data were presented in a poster presentation at the 87th Annual Meeting of the American Thyroid Association (ATA), held October 18-22, 2017, in Victoria, British Columbia.
The results of this study showed that treatment with VK0214 led to statistically significant reductions in plasma levels of multiple very long chain fatty acids (VLCFAs), including the benchmark highly toxic C26 fatty acid, in treated animals compared with vehicle controls. VLCFA levels in CNS tissues were also significantly reduced, suggesting a potential direct benefit in both brain and spinal cord. As the accumulation of VLCFAs is believed to contribute to the underlying pathology of X-ALD, these data provide additional support for the role of selective thyroid receptor beta (TRb) activation as a potential therapeutic approach to the disease.
Key results from the study included:
Treatment with VK0214 produced robust and durable reductions in plasma levels of the lysophosphatidylcholine (LPC) derived C26:0, C24:0, C22:0 and C20:0 very long chain fatty acid esters throughout the study.
Plasma C26:0-LPC levels were reduced by up to 57% through the course of the study, compared to vehicle controls (p < 0.005 at week 6 and p < 0.0001 at weeks 9, 12, 20 and 25).
Plasma C24:0-LPC levels were reduced by up to 61% compared to vehicle controls (p < 0.0001).
Plasma C22:0-LPC levels were reduced by up to 74% compared to vehicle controls (p < 0.0001).
Plasma C20:0-LPC levels were reduced by up to 82% compared to vehicle controls (p < 0.0001).
Importantly, the reductions in plasma VLCFAs were generally maintained or increased in magnitude over the course of the 25-week study, suggesting a potentially progressive and durable effect.
Treatment with VK0214 also led to significant reductions in C26:0, C24:0, C22:0 and C20:0 VLCFA levels in brain, spinal cord and liver tissue.
Brain levels of C20:0-, C22:0-, and C26:0-LPC were reduced by 34%, 12%, and 11%, respectively (p < 0.001, p < 0.05, and p = 0.07, respectively).
Spinal cord levels of C20:0 and C26:0 were reduced by 9%, and 15%, respectively (p < 0.05 for each).
Liver levels of C20:0, C24:0, and C26:0 were reduced by 59%, 49% and 19%, respectively (p < 0.0001, p < 0.0001, and p < 0.05, respectively).
Treatment with VK0214 stimulated significant increases in ABCD2 transporter expression, as assessed by quantitative polymerase chain reaction (qPCR) analysis. Brain ABCD2 expression increased by 35% (p < 0.05) and liver ABCD2 expression increased by 262% (p < 0.05), compared with vehicle controls. These increases are consistent with the proposed mechanism of TRb-mediated reductions in VLCFA levels, as ABCD2 is regulated by TRb and known to play a role in VLCFA metabolism.
"These results are particularly exciting as they demonstrate the first evidence of VK0214's effects in CNS tissues," said Brian Lian, Ph.D., chief executive officer of Viking. "The observed reductions in brain and spinal cord VLCFAs, combined with the stimulation of brain ABCD2 expression suggest potential benefits in tissues that are difficult to penetrate and especially prone to degeneration in X-ALD. In addition to the potent and durable reductions of plasma VLCFAs, we believe these results provide compelling support for the continued evaluation of VK0214 in this setting."
The 25-week proof-of-concept study, conducted at the Kennedy Krieger Institute under a sponsored research agreement with Viking, was designed to evaluate changes in VLCFA levels in the ABCD1 knockout mouse model. This model is intended to mirror the loss of ABCD1 transporter activity that is considered the hallmark of X-ALD. Mice received oral VK0214 or vehicle daily for 25 weeks. Plasma VLCFA levels were determined by measuring unsaturated lysophosphatidylcholine fatty acid esters, which are biomarkers for VLCFAs in X-ALD. Additional work is underway to better understand VK0214's therapeutic effect in models of this disease, including an elucidation of anti-inflammatory properties that have been observed in preliminary studies in human macrophages.
About VK0214
VK0214 has been granted orphan drug status by the U.S. Food and Drug Administration for the treatment of X-linked adrenoleukodystrophy. The molecule is a novel, orally available thyroid receptor beta (TRß) agonist that selectively modulates lipoprotein and triglyceride levels in liver tissue. This mechanism has been demonstrated to affect the expression of the genes that are relevant to the manifestation of X-ALD. In X-ALD, mutations in the ABCD1 gene lead to the accumulation of very long-chain fatty acids (VLCFAs) which is believed to be a fundamental cause of the disease. Research has shown that increasing the expression of the ABCD2 gene can counteract this process and lead to normalization of VLCFA levels. In preclinical studies, VK0214 has been shown to induce expression of ABCD2 by increasing TRß activity, leading to the belief that it may provide therapeutic benefit to X-ALD patients.
About X-ALD
X-ALD is a rare and often fatal metabolic disorder characterized by a breakdown in the protective barriers surrounding brain and nerve cells; a process known as demyelination. The disease, for which there is no approved treatment, is caused by mutations in a peroxisomal transporter of VLCFAs, known as ABCD1. As a result, transporter function is impaired and patients are unable to efficiently metabolize VLCFA. The resulting accumulation can trigger a rapid, inflammatory demyelination, which leads to cognitive impairment, motor skill deterioration, and even death. X-ALD is estimated to occur in approximately 1 in 17,000 births.
The thyroid beta receptor is known to regulate expression of an alternative VLCFA transporter, known as ABCD2. Various preclinical models have demonstrated that increased expression of ABCD2 can lead to normalization of VLCFA metabolism.
That is why it's important that Management get this stock over 5.00 so Big Institutional buying takes it to 20.00 next year. Big banks / Institutional buying starts at 5.00.
Premium Medicinal Cannabis with Professional Service
https://www.letsblum.com/
New Zealand to Vote on Marijuana Law Reform
https://hightimes.com/news/new-zealand-vote-marijuana-law-reform/
Looking forward to another great week, expecting P2 results by no later than next week. 7.00 target.
The death rate among Hip Fracture patients is Why The FDA will take vk5211 into consideration in its decision to approve. There are no other drugs on Market for this, and its much needed. VXTX will be the first for this indication , but what makes it even more exciting is it can be used for Leg fractures and Knee replacement patients as well...it could turn out to be a major Blockbuster drug.
VKTX
Looking strong , holding all its gains today...Vk5211 P2 results are close. GLTA
Here's What's Going To Keep The Viking Therapeutics Inc (NASDAQ:VKTX) Run Going
https://insiderfinancial.com/viking-therapeutics-inc-nasdaqvktx-is-running-heres-why/172895/
congrats ...a win is a win...
Told you this will close strong today... its going to 7.00 on Vk5211 results very very soon....tell everybody.
Wish you all the best man ..peace... Go VKTX
That's what happens when you ignore the fundementals and upcoming catalysts in a stock and you just look at a chart for a stall in action to short....you end up getting short squeezed.
VKTX pattern recently is it likes to run at the end of the day....Enjoy.
Go ahead and check the valuation difference in MDGL and VKTX and you will see VKTX is going for a long ride UP !
sounds like you shorted and are having another bad day...lol
Go VKTX
As you can see The Chart just had a Golden cross, They are expecting news from Phase 2 vk5211 trial at any moment , 5211 potential is 2 billion in sales. Also I doubt the stock will selloff much after great results because they have another Phase 2 trial vk2809 expected results Q1. And that drug is worth 500 million in Market cap if you want to compare it to MDGL drug is in same stage.
VKTX is going to have a 25.00 price tag next year.
Short squeezes are funny....
VKTX going to 7.00 on Phase 2 data coming out very soon.
Holy Cow, VKTXW warrants are soaring high 1.46 now...congrats buddy !!!
Hey Clay , you are known to short stocks right ? ...Please short VKTX right before they release VK5211 results and get squeezed to 7.00 .
Building a solid support base at .19 , TRTC will be moving up strong in November.
AASLD Presentation Will bring a big boost in stock on Monday. GLTA
VKTX ripping ...shock and Awe Baby !!!!!!!
Go VKTX
I'm Thinking we find out more when they meet with the FDA in Q1 to set up Phase 3 vk5211 trial .
That Federal court case could get Cannabis .... Rescheduled.
How a 12-Year-Old Girl Could Help End Weed Prohibition in America
A federal lawsuit claims the ban on bringing medical marijuana across state lines violates an epileptic girl's constitutional rights
http://www.rollingstone.com/culture/features/how-a-12-year-old-girl-could-help-end-weed-prohibition-w507833
Can they do a Bone study trial in Phase 3 for Osteoporosis along with the Hip Fracture Indicator ?
Wow what a great VKTX article !!! So many great points by the writer.
https://seekingalpha.com/article/4114098-viking-therapeutics-conquering-market-aging-therapies
Thanks buddy, Glad you are here sailing with us in this Viking ship.
I do not expect him to read it lol, but hope he does.
VKTX
Message to our CEO....get your ass in the office and compile that data that is sitting on your desk..
No more delays, your shareholders deserve to be treated well after holding all summer while you delayed trials.
according to the timeline 14 weeks is almost up on October 23. I expect a timely release . Get to it and do not make excuses. You are supposed to be a leader....show us you are !!!!!
Go VKTX
Holding strong, MM's cant take my shares...They will have to Pry them from my cold dead hands before they can have them.
VKTX
The IBB is green right now still up...Trump cant do much about this.
California Recreational will be a game changer. TRTC PPS will move up.
I get it ...I'm not worried about Random chance with VK5211...the drug works.